Distillate Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Distillate Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.2M	Buy	+67,092	New	+$14.7M	0.84%	60
2026 Q1	–	Sell	-109,828	Closed	-$18.7M	–	135
2025 Q4	$18.7M	Sell	109,828 -1,555	-1%	-$238K	0.96%	35
2025 Q3	$14.7M	Buy	111,383 +3,572	+3%	+$428K	0.76%	66
2025 Q2	$11.4M	Sell	107,811 -16,774	-13%	-$1.82M	0.61%	98
2025 Q1	$15.5M	Buy	124,585 +1,266	+1%	+$165K	0.79%	58
2024 Q4	$15.2M	Sell	123,319 -27,830	-18%	-$3.28M	0.75%	83
2024 Q3	$16.8M	Buy	151,149 +19,733	+15%	+$2.16M	0.84%	44
2024 Q2	$14M	Buy	+131,416	New	+$14.4M	0.74%	78
2023 Q2	–	Sell	-72	Closed	-$10.5K	–	33
2023 Q1	$10.5K	Buy	+72	New	+$10.7K	2.7%	26
2021 Q4	–	Sell	-17,360	Closed	-$2.26M	–	118
2021 Q3	$2.26M	Buy	+17,360	New	+$2.62M	0.6%	99

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Distillate Capital Partners's JAZZ Position: Q2 2026 in Review

Distillate Capital Partners opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 67,092 shares worth $16.2M. The stake represents 0.84% of the portfolio and ranks #60 among its holdings. This is a return to the name: Distillate Capital Partners previously reported a position in JAZZ as recently as Q4 2025.

Distillate Capital Partners first reported a position in JAZZ in Q3 2021 and has held it in 10 quarters since. The position peaked at $18.7M in Q4 2025. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Distillate Capital Partners held 67,092 shares of Jazz Pharmaceuticals worth $16.2M as of Q2 2026.
Jazz Pharmaceuticals was a new Distillate Capital Partners position in Q2 2026.
Jazz Pharmaceuticals made up 0.84% of Distillate Capital Partners's portfolio in Q2 2026, its #60 holding.
Distillate Capital Partners first reported a position in Jazz Pharmaceuticals in Q3 2021 and has held it in 10 quarters since.
Distillate Capital Partners's Jazz Pharmaceuticals position peaked at $18.7M in Q4 2025.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Distillate Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.